Skip to content
Screener

Pre-Tax Income at other companies

Pfizer logo
PfizerPFE
-$653M-121%
Cardinal Health logo
Cardinal HealthCAH
$392M-41.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$37.1M+252%
Cencora logo
CencoraCOR
$996.39M+11.2%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$299.2M+372%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$166.3M-890%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Increase in tax receivable agreement liability(2,439)(4,420)(106)(15,107)
Other income, net6531,6041,3952,122
Total other expense, net(58,779)(59,661)(120,375)(122,522)
Income before income taxes70,99051,711151,16689,197
Provision for income taxes1,37616,1013,55228,969
Net income69,61435,610147,61460,228
Less: Net income attributable to non-controlling interests(11,952)(13,193)(27,696)(25,616)
Net income attributable to Amneal Pharmaceuticals, Inc.$57,662$22,417$119,918$34,612

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s pre-tax income?
Amneal Pharmaceuticals, Inc. (AMRX) reported pre-tax income of $70.99M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
Amneal Pharmaceuticals, Inc.'s pre-tax income increased by 37.3% year-over-year, from $51.71M to $70.99M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s pre-tax income?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s pre-tax income has grown at a -17.5% compound annual growth rate (CAGR), from -$248.13M to $139.21M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Amneal Pharmaceuticals, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude